These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6828620)

  • 1. Number of nonassessable items and Cooperation level of the retarded during systematic dyskinesia examinations.
    Kalachnik JE; Kidd-Nielsen P; Harder SR
    Psychopharmacol Bull; 1983; 19(1):16-9. PubMed ID: 6828620
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Sprague RL; Kalachnik JE; Slaw KM
    Ment Retard; 1989 Jun; 27(3):141-8. PubMed ID: 2739567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic dyskinesia examination of profoundly mentally retarded persons: cooperation and assessment.
    Granger DA; Yurkunski JM; Miller NH; Swanson JM; Crinella FC
    Am J Ment Defic; 1987 Sep; 92(2):155-60. PubMed ID: 2893551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Matson JL; Fodstad JC; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dyskinesia identification system--Coldwater (DIS-Co): a tardive dyskinesia rating scale for the developmentally disabled.
    Sprague RL; Kalachnik JE; Breuning SE; Davis VJ; Ullmann RK; Cullari S; Davidson NA; Ferguson DG; Hoffner BA
    Psychopharmacol Bull; 1984; 20(2):328-38. PubMed ID: 6728999
    [No Abstract]   [Full Text] [Related]  

  • 6. Validation of tardive dyskinesia as measured on the Dyskinesia Identification System--Coldwater.
    Bostrom AC; Walker MK
    Nurs Res; 1990; 39(5):274-9. PubMed ID: 2399131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.
    Kalachnik JE; Sprague RL
    J Clin Psychol; 1993 Mar; 49(2):177-89. PubMed ID: 8098048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychoactive drug use in public and community residential facilities for mentally retarded persons.
    Intagliata J; Rinck C
    Psychopharmacol Bull; 1985; 21(2):268-78. PubMed ID: 4001291
    [No Abstract]   [Full Text] [Related]  

  • 9. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy.
    Bodfish JW; Newell KM; Sprague RL; Harper VN; Lewis MH
    Am J Ment Retard; 1996 Sep; 101(2):118-29. PubMed ID: 8883667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of states' practices on the use of psychotropic medication.
    Rinck C; Guidry J; Calkins CF
    Am J Ment Retard; 1989 May; 93(6):657-68. PubMed ID: 2719848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychoactive drug treatment in retarded populations.
    Psychopharmacol Bull; 1982 Jan; 18(1):50-66. PubMed ID: 6124020
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of side effects including tardive dyskinesia.
    Campbell M; Palij M
    Psychopharmacol Bull; 1985; 21(4):1063-80. PubMed ID: 4089101
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of single, double-blind procedures, maintenance of placebo effects, and drug-induced dyskinesia with mentally retarded persons--a brief report [proceedings].
    Breuning SE; Ferguson DG; Cullari S
    Psychopharmacol Bull; 1981 Jan; 17(1):122-3. PubMed ID: 7232641
    [No Abstract]   [Full Text] [Related]  

  • 14. [How should mentally handicapped adults with depressive disorders be treated psychopharmacologically?].
    Meins W
    Nervenarzt; 1996 Mar; 67(3):216-8. PubMed ID: 8901279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psychotropic medicines to patients with mental retardation].
    Bygdnes AM; Kristiansen A
    Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1028-30. PubMed ID: 17457386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment with psychotropic drugs in various facilities for mentally handicapped patients].
    Meins W; Auwetter J; Krausz M; Turnier Y
    Nervenarzt; 1993 Jul; 64(7):451-5. PubMed ID: 8103571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices.
    Holden B; Gitlesen JP
    Res Dev Disabil; 2004; 25(6):509-21. PubMed ID: 15541629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facial stereotypic movements and tardive dyskinesia in a mentally retarded population.
    Sprague RL; van Emmerik RE; Slobounov SM; Newell KM
    Am J Ment Retard; 1996 Jan; 100(4):345-58. PubMed ID: 8718990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation.
    Madrid AL; State MW; King BH
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):225-43, x-xi. PubMed ID: 10674198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotropic drugs in group homes: prevalence and relation to demographic/psychiatric variables.
    Aman MG; Sarphare G; Burrow WH
    Am J Ment Retard; 1995 Mar; 99(5):500-9. PubMed ID: 7779345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.